Enterin is a clinical stage biopharmaceutical company dedicated to developing innovative treatments that specifically target the gut-brain axis and modify the progression of neurodegenerative disorders. Through extensive research, Enterin has made significant contributions to understanding the connection between infection and the enteric nervous system (ENS) in immune defense. By investigating the impact of gastrointestinal tract insults on neural communication between the ENS and the central nervous system (CNS), Enterin has shed light on the relationship between immune defense, aging, and neurodegeneration.

Leveraging these findings, Enterin is at the forefront of developing pharmacologic interventions to repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. Their lead compound, ENT-01, has shown promising results in animal models of Parkinson's Disease by displacing alpha-synuclein aggregates and improving neural signaling between the gut and the brain. Clinical trials have demonstrated the improvement of both motor and non-motor symptoms in Parkinson's Disease patients, as well as unexpected normalization of circadian rhythm.

Enterin is also developing ENT-03, a compound that reverses central insulin resistance and targets obesity, type 2 diabetes, and Alzheimer's Disease. Their ultimate goal is to gain insight into how to delay the aging process, prevent neurodegeneration, and ultimately extend the lifespan of patients with these conditions